Dr. Leighton is a highly-seasoned medicinal chemistry and pharmaceutical executive with over 30 years experience in the pharmaceutical (Glaxo) and biotechnology industries. While at Glaxo, he discovered/developed drugs including Ultiva, Wellbutrin, Atracuriun, Acrivastine, and AZT that generate over $4 billion per year for the pharmaceutical industry. Dr. Leighton was Group Chairman for Cardiovascular Diseases with responsibility for Glaxo’s global cardiovascular drug development programs.
Since leaving Glaxo, he founded and has been actively involved in the conceptualization and start-up of a number of successful biotech companies such as Inspire Pharmaceuticals and ICAgen, where he attracted quality venture syndicates. Dr. Leighton is currently a consultant working with the venture capital industry to identify quality emerging discovery and clinical opportunities. Dr. Leighton obtained his Ph.D. in Pharmacology from the University of Virginia in 1976.